Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

Cruellas M, Rodriguez-Hernandez A, Carità L, Seguí E, Cejuela M, Lema L, García-Torralba E, Roqué-Lloveras A, Fernández-Ortega A, Melé M, Tapia M, Servitja S, González-Santiago S, Blaya-Boluda N, Bellet M, Martínez-Sáez O, Pimentel I, García-Fructuoso I, Pascual T, Joval-Ramentol L, Viñas G, Rey Aceituno M, Casas A, Castillo E, Brasó-Maristany F, Vivancos A, Serra V, Villacampa G, Oliveira M, Prat A, Saura C, Adamo B, Balmaña J

Open source

DOI: 10.1016/j.esmoop.2026.108335
Published: 2026 Aug
Container: ESMO open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.esmoop.2026.108335,
  title = {Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.},
  author = {Cruellas M and Rodriguez-Hernandez A and Carità L and Seguí E and Cejuela M and Lema L and García-Torralba E and Roqué-Lloveras A and Fernández-Ortega A and Melé M and Tapia M and Servitja S and González-Santiago S and Blaya-Boluda N and Bellet M and Martínez-Sáez O and Pimentel I and García-Fructuoso I and Pascual T and Joval-Ramentol L and Viñas G and Rey Aceituno M and Casas A and Castillo E and Brasó-Maristany F and Vivancos A and Serra V and Villacampa G and Oliveira M and Prat A and Saura C and Adamo B and Balmaña J},
  year = {2026},
  journal = {ESMO open},
  doi = {10.1016/j.esmoop.2026.108335},
  url = {https://doi.org/10.1016/j.esmoop.2026.108335}
}

RIS

TY  - JOUR
TI  - Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.
AU  - Cruellas M
AU  - Rodriguez-Hernandez A
AU  - Carità L
AU  - Seguí E
AU  - Cejuela M
AU  - Lema L
AU  - García-Torralba E
AU  - Roqué-Lloveras A
AU  - Fernández-Ortega A
AU  - Melé M
AU  - Tapia M
AU  - Servitja S
AU  - González-Santiago S
AU  - Blaya-Boluda N
AU  - Bellet M
AU  - Martínez-Sáez O
AU  - Pimentel I
AU  - García-Fructuoso I
AU  - Pascual T
AU  - Joval-Ramentol L
AU  - Viñas G
AU  - Rey Aceituno M
AU  - Casas A
AU  - Castillo E
AU  - Brasó-Maristany F
AU  - Vivancos A
AU  - Serra V
AU  - Villacampa G
AU  - Oliveira M
AU  - Prat A
AU  - Saura C
AU  - Adamo B
AU  - Balmaña J
PY  - 2026
JO  - ESMO open
DO  - 10.1016/j.esmoop.2026.108335
UR  - https://doi.org/10.1016/j.esmoop.2026.108335
ER  -

APA

M, C., A, R., L, C., E, S., M, C., L, L., E, G., A, R., A, F., M, M., M, T., S, S., S, G., N, B., M, B., O, M., I, P., I, G., T, P., L, J., G, V., M, R. A., A, C., E, C., F, B., A, V., V, S., G, V., M, O., A, P., C, S., B, A., & J, B. (2026). Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.. ESMO open. https://doi.org/10.1016/j.esmoop.2026.108335

Source records

pubmed · retrieved 2026-11-11T01:14:37.727Z